The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials
Open accessAbstract
PURPOSE: Women have more adverse events (AEs) from chemotherapy than men, but few studies have investigated sex differences in immune or targeted therapies. We examined AEs by sex across different treatment domains. METHODS: We analyzed treatment-related AEs by sex in SWOG phase II and III clinical trials conducted between 1980 and 2019, excluding sex-specific cancers. AE codes and grade were categorized using the Common Terminology Criteria for Adverse Events. Symptomatic AEs were defined as those aligned with the National Cancer Institute's Patient-Reported Outcome–Common Terminology Criteria for Adverse Events; laboratory-based or observable/measurable AEs were designated as objective (hematologic v nonhematologic). Multivariable logistic regression was used, adjusting for age, race, and disease prognosis. Thirteen symptomatic and 14 objective AE categories were examined. RESULTS: In total, N = 23,296 patients (women, 8,838 [37.9%]; men, 14,458 [62.1%]) from 202 trials experiencing 274,688 AEs were analyzed; 17,417 received chemotherapy, 2,319 received immunotherapy, and 3,560 received targeted therapy. Overall, 64.6% (n = 15,051) experienced one or more severe (grade ≥ 3) AEs. Women had a 34% increased risk of severe AEs compared with men (odds ratio [OR] = 1.34; 95% CI, 1.27 to 1.42; P < .001), including a 49% increased risk among those receiving immunotherapy (OR = 1.49; 95% CI, 1.24 to 1.78; P < .001). Women experienced an increased risk of severe symptomatic AEs among all treatments, especially immunotherapy (OR = 1.66; 95% CI, 1.37 to 2.01; P < .001). Women receiving chemotherapy or immunotherapy experienced increased severe hematologic AE. No statistically significant sex differences in risk of nonhematologic AEs were found. CONCLUSION: The greater severity of both symptomatic AEs and hematologic AEs in women across multiple treatment modalities indicates that broad-based sex differences exist. This could be due to differences in AE reported, pharmacogenomics of drug metabolism/disposition, total dose received, and/or adherence to therapy. Particularly large sex differences were observed for patients receiving immunotherapy, suggesting that studying AEs from these agents is a priority.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Koenker, R., & Bassett, G. (1978) · Econometrica · doi:10.2307/1913643 · Cited by 13,316
Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials
Hutchins, L. F., Unger, J. M., Crowley, J. J., Coltman, C. A., & Albain, K. S. (1999) · New England Journal of Medicine · doi:10.1056/nejm199912303412706 · Cited by 2,174
Self-citationSex Differences in Pharmacokinetics and Pharmacodynamics
Soldin, O. P., & Mattison, D. R. (2009) · Clinical Pharmacokinetics · doi:10.2165/00003088-200948030-00001 · Cited by 1,163
Basch, E., Reeve, B. B., Mitchell, S. A., Clauser, S. B., Minasian, L. M., Dueck, A. C., Mendoza, T. R., Hay, J., Atkinson, T. M., Abernethy, A. P., et al. (2014) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/dju244 · Cited by 1,151
Self-citationCardiovascular Disease in Women: Clinical Perspectives
Garcia, M., Mulvagh, S. L., Bairey Merz, C. N., Buring, J. E., & Manson, J. E. (2016) · Circulation Research · doi:10.1161/circresaha.116.307547 · Cited by 1,080
Considering how biological sex impacts immune responses and COVID-19 outcomes
Scully, E. P., Haverfield, J., Ursin, R. L., Tannenbaum, C., & Klein, S. L. (2020) · Nature Reviews Immunology · doi:10.1038/s41577-020-0348-8 · Cited by 932
Allikmets, R., Schriml, L. M., Hutchinson, A. A., Romano-Spica, V., & Dean, M. C. (1998) · PubMed · Cited by 798
Insomnia and Risk of Cardiovascular Disease
Javaheri, S., & Redline, S. (2017) · Chest · doi:10.1016/j.chest.2017.01.026 · Cited by 714
Patient Characteristics Associated with Medication Adherence
Rolnick, S. J., Pawloski, P. A., Hedblom, B. D., Asche, S. E., & Bruzek, R. J. (2013) · Clinical Medicine & Research · doi:10.3121/cmr.2013.1113 · Cited by 481
Sex differences in physical symptoms: The contribution of symptom perception theory
van Wijk, C. M. T. G., & Kolk, A. M. (1997) · Social Science & Medicine · doi:10.1016/s0277-9536(96)00340-1 · Cited by 471
Cited by
Evaluation and Mitigation of Racial Bias in Clinical Machine Learning Models: Scoping Review
Huang, J., Galal, G., Etemadi, M., & Vaidyanathan, M. (2022) · JMIR Medical Informatics · doi:10.2196/36388 · Cited by 186
The problem with one-size-fits-all medicine: biological sex and the aging immune system
Baker, C., Ansere, V. A., Sanqui, C. I., & Benayoun, B. A. (2026) · PLOS Biology · doi:10.1371/journal.pbio.3003763 · Cited by 3
Metadata
- Authors
- Unger, J. M., Vaidya, R., Albain, K. S., LeBlanc, M., Minasian, L. M., Gotay, C. C., Henry, N. L., Fisch, M. J., Lee, S. M., Blanke, C. D., & Hershman, D. L.
- Venue
- Journal of Clinical Oncology
- Published
- 2022-05-01
- Volume
- 40
- Issue
- 13
- Pages
- 1474-1486
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W4210620015
- Cited by
- 320
- References
- 42
- FWCI
- 51.36
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. https://app.cochat.ai/papers/10.1200/jco.21.02377
- The paper
- Unger, J. M., Vaidya, R., Albain, K. S., LeBlanc, M., Minasian, L. M., Gotay, C. C., Henry, N. L., Fisch, M. J., Lee, S. M., Blanke, C. D., & Hershman, D. L. (2022). Sex Differences in Risk of Severe Adverse Events in Patients Receiving Immunotherapy, Targeted Therapy, or Chemotherapy in Cancer Clinical Trials. Journal of Clinical Oncology. https://doi.org/10.1200/jco.21.02377
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.